
Please try another search
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Carl L. Gordon | 59 | 2015 | Independent Chairman |
Edward Chu | - | 2022 | Member of Clinical Advisory Board |
Thomas J. Schuetz | 64 | 2015 | CEO & Vice Chairman |
F. Stephen Hodi | - | 2019 | Member of Clinical Advisory Board |
Philip J. Ferneau | 62 | 2015 | Independent Director |
Richard Goldberg | - | 2022 | Member of Clinical Advisory Board |
Mary Ann Gray | 72 | 2022 | Independent Director |
Richard S. Lindahl | 61 | 2023 | Independent Director |
James Patrick Boylan | 57 | 2022 | Independent Director |
Ellen V. Chiniara | 66 | 2022 | Independent Director |
Patricia M. LoRusso | - | 2022 | Member of Clinical Advisory Board |
Daniel Douglas Von Hoff | 77 | 2022 | Member of Clinical Advisory Board |
Howard S. Hochster | - | 2022 | Member of Clinical Advisory Board |
Edward Chu | - | 2022 | Member of Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review